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The onset of DNA replication is an important step within the life cycle of the human neurotropic polyomavirus JC. In this
report, evidence that both the human and the murine tumor suppressor protein p53 strongly inhibit JCV DNA replication in
vivo is presented. This inhibition is dose-dependent and not a secondary effect of a decreased expression of JCV large T-
antigen in response to p53. Using deletion mutants of murine p53 and tumor-derived point mutations of human p53, the
basis of the suppression of JCV DNA replication by p53 was dissected. Deletion of either the amino- or the carboxy-terminal
domain of murine p53 did not interfere with the repression of JCV DNA replication. However, deletion of the highly conserved
central region of p53 abolished the inhibitory effect on replication. The tumor-derived human mutant p53(His273) inhibited
JCV DNA replication significantly, whereas another tumorigenic mutant, p53(His175), had no inhibitory effect. Concomitantly,
a direct protein–protein interaction between p53 and JCV large T-antigen was lost in mutants which did not affect JCV DNA
replication. These results strongly suggest that p53 inhibits JCV DNA replication by interacting with JCV large T-antigen.
q 1996 Academic Press, Inc.
INTRODUCTION SV40 large T-antigen appears to be important for the
immortalization of rodent and human cells (Lin and Sim-
JC virus (JCV), a member of the papovavirus family, is mons, 1991; Zhu et al., 1991). The basis for JCV’s re-
the etiologic agent of progressive multifocal leu- stricted transforming behavior might be the difference in
koencephalopathy in human (for review see Berger and complex formation between JCV large T-antigen and p53
Concha, 1995). Exposure to JC virus usually occurs early (Trowbridge and Frisque, 1993).
in life and results in the persistence of an archetypic
The p53 gene is the most frequently mutated gene
virus in a large percentage of the human population.
found in human cancers and has been established as a
Reactivation of the latent virus in individuals suffering
tumor suppressor gene (for reviews see Levine et al.,from immunosuppression can lead to selective infection
1991; Donehower and Bradley, 1993; Prives and Man-and cytolytic destruction of the myelin-producing oligoden-
fredi, 1993). In vitro transformation assays have revealeddrocytes of the central nervous system and results in
that wild-type p53 inhibits cell transformation induced bysevere demyelination. Viral isolates from infected brain
activated oncogenes (Eliyahu et al., 1989). Inactivation oftissue, such as prototypic JC viral strain MAD-1 (Frisque
the p53 gene plays a critical role in malignant transforma-et al., 1984), exhibit a marked specificity for glial cells
tion, probably by allowing cells to escape from normal(Kenney et al., 1984). The tissue tropism of JCV is defined
growth control. Previous studies have demonstrated thaton the level of transcription and is conferred by the hyper-
wild-type p53 can mediate direct growth arrest of prolifer-variable noncoding region, which not only serves as ori-
ating cells at the G1 –S boundary (Diller et al., 1990; Marti-gin of DNA replication (Lynch and Frisque, 1990; Sock
nez et al., 1991). Accumulating evidence suggests thatet al., 1991, 1993) but also as promoter for the early
p53 may be directly involved in the regulation of DNAregulatory and the late capsid genes (Kenney et al.,
replication. For example, murine and human wild-type1984). Unlike the tissue specificity of the early gene activ-
p53 inhibits the SV40 DNA replication in vivo (Braithwaiteity, viral DNA replication occurs in any primate cell type
et al., 1987) and in vitro (Friedmann et al., 1990; Wang etwhen the early protein, T-antigen, is provided (Feigen-
al., 1989). Murine and human wild-type p53 binds to thebaum et al., 1987). In contrast to simian virus 40 (SV40),
SV40 large T-antigen, which acts as a helicase and alsoJCV is highly restricted in its ability to transform cells in
binds to the cellular DNA polymerase a (Gannon andculture (Walker and Frisque, 1986). Binding of p53 by
Lane, 1987). The central highly conserved domain of p53
is responsible for this interaction (Tan et al., 1986; Jenkins
1 Both authors contributed equally to this work and should be consid- et al., 1988). Wild-type p53 inhibits the initiation and prop-
ered primary authors. agation of SV40 DNA replication, most likely by pre-2 To whom reprint requests should be addressed at Institut fu¨r Bio-
venting DNA unwinding by the large T-antigen helicasechemie, Am Hubland, D-97074 Wu¨rzburg, Germany. Fax: /49 931
8884045. E-mail: grummt@biozentrum.uni-wuerzburg.de. (Wang et al., 1989). p53 was also found to relocate to
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the sites of DNA replication in herpes virus-infected cells a buffer containing 1% Nonidet P-40, 150 mM NaCl, and
50 mM Tris–HCl, pH 8.0.(Wilcock and Lane, 1991), indicating that p53 may interact
directly with components of the DNA replication machin-
Plasmids and construction of p53 deletion mutantsery. In support of this observation, purified p53 has re-
cently been shown to bind the cellular replication factor
pJC433 is a pUC18-based plasmid containing the se-
A in vitro (Dutta et al., 1993; He et al., 1993; Li and
quence of JC virus (Mad-1 strain) from map positions
Botchan, 1993).
4981 to 279 (Sock et al., 1993). The plasmid pRSV–JCT
Unlike the well-studied interaction of p53 with SV40
which expresses JCV large T-antigen has been described
large T-antigen (reviewed in Ludlow, 1993) and its influ-
before (Sock et al., 1993).
ence on SV40 DNA replication (Friedman et al., 1990;
Plasmids with cDNA sequences for mouse p53 were
Wang et al., 1989; Braithwaite et al., 1987), little is known
a generous gift of Dr. V. Rotter. In order to construct a
about the interaction between p53 and JCV large T-anti-
series of p53 deletion mutants, the coding sequence for
gen. Early studies found either no evidence for a protein
wild-type mouse p53 was inserted into pBKS-II/ (Stra-
complex between JCV large T-antigen and p53 in JC vi-
tagene) as an EcoRI/HindIII fragment. For in vitro muta-
rus-infected human fetal brain or kidney cells (Major and
genesis two synthetic oligonucleotides were used to in-
Traub, 1986) or the interaction was limited to the large
troduce an AflII restriction site and a stop codon into the
T-antigen of JCV-586, a strain which was isolated from
p53 cDNA (oligonucleotide 1: 5* TGGGAACCTT CTGTGA-
owl monkey astrocytoma cells and differed from both the
CGCT TAAGCTTTGA GGTTCGTGTT TG 3*, oligonucleo-
Mad-1 and Mad-4 strains (Major et al., 1987). Bollag et
tide 2: 5* CAAAGAGAGC GCTGCCCTGA TGCTTAAGCG
al. (1989) reported that the subpopulation of large T-anti-
CCTCTCCCCC G 3*; changed residues are underlined,
gen that forms a complex with cellular p53 in Rat2 cells
AflII sites bold typed, and stop codons in italics). The
is smaller in JCV-transformed cells than in SV40- or BK
deletion mutants D10/34, D10/71, D10/213, D10/266,
virus-transformed cells. It was further reported that the
D10/310 were constructed by combination of the first
ratio of JCV large T-antigen to p53 in the corresponding
EcoRV restriction site within the p53 cDNA with EcoRV
complex in Rat2 cells differs from the stoichiometry found
(D10/34), PpuMI (D10/71), DraIII (D10/213), AflII (intro-
for the complex between SV40 large T-antigen and p53
duced by oligonucleotide 1; D10/266), or AflII (introduced
(Trowbridge and Frisque, 1993).
by oligonucleotide 2; D10/310) restriction sites, respec-
In this study we show that wild-type human and the
tively. The deletion mutants D71/213, D71/266, D71/310
highly homologous wild-type murine p53 inhibit the repli-
were constructed by combination of the PpuMI restriction
cation of JCV in human glial cells. The central domain of
site with DraIII (D71/213), AflII (introduced by oligonucle-
murine p53 is essential for this suppression of JCV DNA
otide 1; D71/266), or AflII (introduced by oligonucleotide
replication. A tumor-derived mutant human p53, (His273),
2; D71/310) restriction sites, respectively. The deletion
did also inhibit JCV DNA replication, whereas another
mutants D213/266, D213/310 were constructed by com-
mutant, p53 (His175), had no such effect. Furthermore
bination of the DraIII restriction site with AflII (introduced
we present evidence that binding of p53 to JCV large T-
by oligonucleotide 1; D213/266), or AflII (introduced by
antigen is responsible for the repression of JCV origin-
oligonucleotide 2; D213/310) restriction sites, respec-
dependent DNA replication in vivo.
tively. The deletion mutants D262/390 and D306/390
were constructed by insertion of a stop codon by oligonu-
MATERIALS AND METHODS cleotide 1 and 2, respectively. Plasmids with cDNA se-
quences for human p53 were a generous gift of Dr. B.Cells and baculovirus
Vogelstein. p53 cDNAs were inserted into the expression
U138 and U87MG human glioblastoma cells were vector pSG5 (Green et al., 1988) as EcoRI/HindIII frag-
propagated in RPMI 1640 and EMEM medium, respec- ments for murine wild-type and mutant p53 and as BamHI
tively, supplemented with 10% fetal calf serum at 377 and fragments for human wild-type and mutant p53.
5% CO2 . Spodoptera frugiperda insect cells (Sf9) were
grown in TC100 medium supplemented with 10% fetal Replication assay
calf serum at 277 and infected at an m.o.i. of 10 with
U138 and U87MG human glioblastoma cells wererecombinant baculovirus vJCTHxaII which expresses the
plated at a density of 5 1 105 per 6-cm dish in DMEMlarge T-antigen of JC virus.
medium supplemented with 10% FCS 24 hr before trans-
fection. Cells were transfected with 1 mg pJC433 andAntibodies
1 mg of p53 expression plasmid applying the calcium
phosphate technique followed by a glycerol boost 16The monoclonal anti-p53 antibodies PAb421 and RA3-
2C2 as well as the anti-SV40 T-antigen antibody PAb416, hr posttransfection. The JCV T-antigen was supplied by
cotransfection of 1 mg of pRSV–JCT. At 72 hr post-which cross-reacts with the JCV large T-antigen, were
purified from supernatants of hybridoma cells by chroma- transfection cells were harvested and low-molecular-
weight DNA was extracted according to Hirt (1967). Repli-tography on protein A–Sepharose and dialyzed against
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cation was assayed by testing the DpnI sensitivity of the antigen interaction (Fig. 1A). Expression of each of the
p53 proteins in U87MG glioblastoma cells was analyzedretrieved plasmid DNA as described (Sock et al., 1991).
Quantification of Southern blots was performed using the by Western blotting using the p53-specific monoclonal
antibodies PAb421 and RA3-2C2. Cells were transfectedImageQuant software on a Molecular Dynamics Phos-
phorImager. Experiments (each performed in triplicates) with 3 mg of the various p53 expression plasmids. Figure
1B demonstrates that all mutants are expressed althoughwere repeated at least three times for each plasmid.
mutants D262/390 and D306/390 could be detected only
with the antibody RA3-2C2 but not with PAb421. FigureExtraction of JCV T-antigen and Western blotting
1C shows the expression of the human wild-type and
mutant p53 proteins, detected with PAb421. EndogenousSf9 cells infected with recombinant baculovirus were
p53 of the U87MG cells was not detected with eitherlysed 48 hr after infection in a buffer containing 1% NP-
antibody, indicating that expression and/or stability might40, 150 mM NaCl, 50 mM Tris–HCl, pH 8.0, 0.5 mM
be extremely low.PMSF, and 1 mg/ml aprotinin at 07 for 30 min. After cen-
trifugation at 15,000 rpm and 47 for 15 min, the superna-
JCV DNA replication is inhibited by expression oftant was collected. For Western blotting protein samples
human and mouse p53were transferred from SDS–PAG (10% polyacrylamide)
onto nitrocellulose filters for 2 hr at 150 mA. Nitrocellu- A plasmid containing the complete regulatory re-
lose was blocked with 10% dry milk in PBS for 2 hr. JCV gion of JC virus (Mad-1) from map positions 4981 to
T-antigen was detected by the anti-T-antigen antibody 279 (pJC433; Sock et al., 1991) which includes the
PAb416, and p53 by the anti-p53 antibodies PAb421 or viral origin of replication was tested for its ability to
RA3-2C2. Primary antibodies were detected by a horse- replicate in the presence of JC virus large T-antigen
radish peroxidase-conjugated polyvalent goat anti- and human or murine p53. The human glioblastoma
mouse Ig secondary antibody and visualized by en- cell lines U138 and U87MG were chosen for these
hanced chemiluminescence (Amersham). studies. The JC virus T-antigen and the human or mu-
rine p53 were expressed transiently in the human glio-
blastoma cells from the expression vectors pRSV – JCTCoimmunoprecipitation of JCV large T-antigen and
and the various pSG5-p53 constructs, respectively,murine p53
which were cotransfected with the replication test
plasmid pJC433. Cotransfection of the expression vec-p53 proteins were transcribed and translated in vitro
tors for both the human and the murine p53 results inusing the TNT-coupled reticulocyte lysate (Promega) ac-
a dose-dependent inhibition of replication of pJC433cording to the manufacturer’s instructions. Monoclonal
in U87MG cells (Fig. 2, Table 1), as well as in U138antibody PAb416 preadsorbed to protein A–Sepharose
cells (Table 1). In the case of the human p53, 0.1 mgwas incubated with [35S]methionine-labeled p53 and ba-
of transfected p53 expression plasmid led to a de-culovirus-produced JC virus T-antigen for 2 hr at 47 in
crease in the replication rate of pJC433 in U87MG cellsbinding buffer (150 mM NaCl, 50 mM Tris–HCl, pH 8.0,
by 14.5%. Transfection of 0.3 and 0.5 mg resulted in aand 1% NP-40). Beads were washed four times with bind-
decrease by 21.3% and 40.7%, respectively, whereasing buffer, boiled in Laemmli sample buffer, and the pro-
at 1 mg the replication of pJC433 is reduced by 75 toteins were size separated by SDS–PAGE (15% polyacryl-
80% (Fig. 2B, Table 1). Similar results were obtainedamide). Coimmunoprecipitated 35S-labeled p53 was de-
for murine p53. Transfection of 0.1 mg p53 expressiontected by autoradiography.
plasmid led to a decrease in the replication rate in
both cell lines by 8.6%. Increasing the amount of
RESULTS transfected expression plasmid to 0.3 and 0.5 mg re-
sulted in a further decrease by 13.4 and 37.8%, respec-
Expression of wild-type and mutant p53 in human tively. After transfection of 1 mg expression plasmid
glioblastoma cells the replication of pJC433 is reduced by 80 to 85% (Fig.
2A, Table 1).
To analyze whether human and murine p53 inhibit JCV
DNA replication, p53 cDNAs were cloned in the expres- The central domain of murine p53 is responsible for
sion vector pSG5. Besides wild-type human p53 we as- inhibition of JCV DNA replication
sayed two tumor-derived human p53 mutants. One of the
mutants—(His 273)—displays the wild-type conforma- To dissect the structural basis of the inhibitory effect
of murine p53 on JCV DNA replication we used dele-tion of human p53, whereas mutant (His175) was shown
to have an altered structural conformation (Lane and Ben- tion mutagenesis to remove distinct domains of mu-
rine p53. The deletion mutants were named by thechimol, 1990). Deletion mutants of murine p53 were spe-
cifically designed to target the conserved regions of mu- amino acids that were preserved (Fig. 1). All mutants
were tested in standard in vivo replication assaysrine p53, including the domains responsible for p53-T-
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FIG. 1. Construction and expression of p53 deletion mutants. (A) Construction of deletion mutants of murine p53 and correlation to structural
domains. A series of deletion mutants of murine p53 was designed and constructed as described under Materials and Methods. The extent of the
deletions generated is indicated. The conserved boxes I to V, the nuclear localization signals, the oligomerisation domain, the N-terminal transactiva-
tion domain, and the binding domains for several proteins are shown below. (B) Expression of wild-type p53 and deletion mutants in U87MG cells.
Cells were transfected with 3 mg of the various p53 expression plasmids. Protein samples were analyzed by Western blotting applying the p53-
specific antibodies PAb421 (a) and RA3-2C2 (b). (C) Expression of wild-type and mutant human p53 in U87MG cells. Cells were transfected with 3
mg of the p53 expression plasmids. Protein samples were analyzed by Western blotting applying the p53-specific antibody PAb421.
upon cotransfection of U138 and U87MG cells with 2). Whereas no replication could be detected in the
absence of JCV T-antigen, pJC433 replicated in thethe replication test plasmid pJC433 and the expression
plasmid for JCV T-antigen pRSV – JCT (Fig. 3, Table presence of JCV T-antigen (Fig. 3). The JCV DNA repli-
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cation in both cell lines was inhibited by p53 to the
same extent. The degree of inhibition of JCV DNA repli-
cation by p53 was virtually unchanged for constructs
that were deleted either in the amino-terminal (D10/
34 and D10/71) or in the carboxy-terminal domains
(D306/390). Removal of the central domain of p53
comprising the conserved boxes II to V, however, abol-
ished the inhibitory effect on the replication activity.
From the series of deletion mutants tested the border
of the inhibitory core domain of p53 can be localized
between amino acids 71 on the amino-terminal side
and 262 near the C-terminus.
Effects of human tumor-derived mutant p53 on JCV
DNA replication
To study whether tumor-derived mutants of human
p53 affect JCV DNA replication in vivo we have ana-
lyzed two different point mutations. One of them (His
273) was previously shown to retain the wild-type con- FIG. 2. (A) Dose-dependent repression of the JC virus replication by
formation of p53, whereas the other one (His 175) dis- wild-type murine p53 in U87MG cells. Cells were transfected with 1
mg pJC433, 1 mg pRSVJCT, and increasing amounts of murine wtp53turbs the structural conformation of the p53 protein.
expression plasmid pSG5–mp53cD. pSG5 plasmid without p53 cDNAThese mutants were tested in standard in vivo replica-
was added to a total amount of transfected DNA of 3 mg. Low-molecu-tion assays upon cotransfection of U87MG cells. Fig-
lar-weight DNA was extracted and analyzed by Southern blotting. Lane
ure 4 and Table 3 demonstrate that JCV DNA replica- 1, Without pSG5-mp53cD; lanes 2 to 5, 0, 0.1, 0.3, 0.5, and 1 mg of
tion was inhibited by wild-type and mutant (His 273) pSG5–mp53cD. Arrow, replicated, DpnI-resistant pJC433 DNA. (B)
Dose-dependent repression of the JC virus replication by wild-typep53. The degree of inhibition was virtually the same
human p53 in U87MG cells. Cells were transfected with 1 mg pJC433,for both p53 proteins. However, the mutant (His175)
1 mg pRSVJCT, and increasing amounts of human wtp53 expressiondid not suppress JCV DNA replication in vivo at all
plasmid pSG5–hp53cD. pSG5 plasmid without p53 cDNA was added
(Fig. 4, Table 3). In conclusion p53 affects JCV DNA to a total amount of transfected DNA of 3 mg. Low-molecular-weight
replication only in wild-type conformation. DNA was extracted and analyzed by Southern blotting. Lane 1, Without
pSG5–hp53cD; lanes 2 to 5, 0, 0.1, 0.3, 0.5, and 1 mg of pSG5–hp53cD.
Arrow, replicated, DpnI-resistant pJC433 DNA.p53 does not repress JCV T-antigen expression
p53 functions as a transcriptional regulator and can
activate transcription when bound to a promoter through
moter we studied the activity of a luciferase reportera p53 response element (Farmer et al., 1992; Funk et al.,
gene which was under the control of the LTR promoter.1992), but it also can negatively regulate a variety of
Cotransfection of the pRSVluc reporter plasmid and thegenes lacking such a response element (Ginsberg et al.,
p53 expression plasmid into U87MG cells revealed that1991; Subler et al., 1994).
increased levels of the p53 expression vector do notWe asked whether coexpression of p53 in U87MG
down-modulate the expression of luciferase (data notcells affects the level of JCV T-antigen necessary for
shown). Thus the LTR promoter driving the JCV T-anti-replication and exerts the observed replicational repres-
gen expression is not impaired by overexpression ofsion this way. Therefore, pRSV–JCT was cotransfected
murine p53.with increasing amounts of pSG5–mp53cD and levels of
JCV T-antigen were analyzed by Western blotting using
p53 interacts physically with JCV T-antigen in vitro
the anti-T-antigen antibody PAb416 and the anti-p53 anti-
body PAb421. pRSV–JCT-transfected cells showed a To investigate whether the inhibition of JCV DNA rep-
lication by p53 directly depends on the interaction ofclearly visible signal at 94 kDa, corresponding to JCV T-
antigen even in the presence of high levels of coex- p53 with JCV T-antigen, coimmunoprecipitation experi-
ments were carried out. For these experiments p53 pro-pressed murine p53 (Fig. 5). Cotransfection of 5 mg of
p53 expression plasmid (lane 4), compared to 1 mg (lane teins were translated in vitro in the presence of [35S]-
methionine. Efficient expression and labeling of p532) used for replication studies, had no effect on the level
of JCV T-antigen expressed in U87MG cells. was analyzed by SDS – PAGE (Fig. 6). Immunoprecipita-
tions were carried out with the anti-T-antigen antibodyIn the in vivo replication system the expression of
JCV large T-antigen is driven by the LTR promoter of PAb416 coupled to protein A – Sepharose. We first dis-
sected the structural basis of the interaction of murinethe Rous sarcoma virus. To find out whether murine
p53 modulates the transcriptional activity of this pro- wild-type and mutant p53 with JCV T-antigen. JCV T-
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TABLE 1
Dose-Dependent Repression of JCV DNA Replication by p53
p53 expression
plasmid 0 mg 0.1 mg 0.3 mg 0.5 mg 1.0 mg
% Replication in U87MG cells Murine 100 { 8.9 91.4 { 12.4 86.6 { 9.3 62.2 { 8.6 15.0 { 15.8
% Replication in U138 cells Murine 100 { 13.8 90.6 { 7.2 88.4 { 5.7 67.3 { 6.3 19.4 { 12.5
% Replication in U87MG cells Human 100 { 6.8 85.5 { 8.9 78.7 { 7.1 59.3 { 8.6 22.5 { 7.3
% Replication in U138 cells Human 100 { 8.3 89.9 { 5.5 75.1 { 6.9 61.7 { 5.9 24.0 { 12.8
antigen and equal amounts of each of the [35S]- and for the repression of T-antigen-dependent JCV DNA
replication.methionine-labeled p53 proteins were incubated and
subsequently precipitated with the anti-T-antigen resin.
Figure 6A clearly shows that [35S]methionine-labeled DISCUSSION
murine wild-type p53 coprecipitates with JCV large T-
DNA replication is an important step in the life cycleantigen. Comparable results were obtained for some
of papovaviruses. Not only are viral progeny genomesof the p53 deletion mutants. Deletion of the N-terminal
produced during this process, but also important
region of p53 (p53D10/34, p53D10/71) or of the C-ter-
changes take place which cause the virus to switch from
minal domain containing the nuclear localization and
the early to the late phase of viral gene expression. DNA
oligomerization signals (p53D306/390) did not interfere
replication has been well studied in SV40; however,
with the ability of p53 to form stable complexes with
much less is known about the mechanism and the regu-
JCV T-antigen (Fig. 6A). However, mutations affecting
lation of DNA replication of the related papovavirus JC.
the central region of the p53 protein (p53D71/213,
The aim of this work was to increase our understanding
p53D71/266, p53D71/310, p53D262/390) lost their
of the replication properties of this virus which is en-
competence for the interaction with JCV T-antigen. demic in humans and can cause PML in immunocom-
In further experiments we analyzed the interaction of promised individuals.
JCV T-antigen with human wild-type and mutant p53 The studies presented here show that p53 represses
(Fig. 6B). Mutant p53 (His 273) bound to JCV T-antigen JCV DNA replication by interacting with JC virus T-antigen
with similar relative affinity as wild-type human p53. which is necessary for initiation and elongation of DNA
Mutant p53 (His 175), however, failed to interact with replication (Feigenbaum et al., 1987). It has been postu-
JCV T-antigen. These results argue that a structurally lated that wild-type p53 plays a negative regulatory role in
intact central region of p53 is necessary and sufficient SV40 DNA replication in vivo, possibly by downregulating
for the interaction between p53 and the JCV T-antigen SV40 DNA replication late in the lytic cell cycle (Gannon
and Lane, 1987; Kienzle et al., 1989; Stu¨rzbecher et al.,
1988; Wang et al., 1989). This negative regulatory effect
of p53 in SV40 DNA replication often is considered a
TABLE 2
Replicational Repression by Wild-Type p53 and Deletion Mutants
% Replication % Replication
p53 in U138 cells in U87MG cells
Mock 100 { 13.8 100 { 8.9
wt 19.4 { 7.2 15.0 { 12.4
D10/34 20.1 { 5.4 16.4 { 9.3
D10/71 19.8 { 6.2 16.3 { 7.5
D10/213 94.1 { 10.6 97.9 { 8.4
D10/266 93.9 { 3.1 104.3 { 9.7
D10/310 93.8 { 7.5 97.6 { 5.4
D71/213 91.9 { 6.9 97.4 { 10.3
FIG. 3. Repression of JCV DNA replication by p53 deletion mutants. D71/266 92.4 { 8.9 94.9 { 7.4
U87MG cells were transfected with 1 mg of each of the expression D71/310 93.2 { 8.1 95.2 { 7.9
plasmids pJC433, pRSV–JCT and pSG5–mp53, respectively. Low-mo- D262/390 92.5 { 7.9 97.3 { 4.3
lecular-weight DNA was extracted and analyzed by Southern blotting. D306/390 18.1 { 15.6 13.7 { 14.3
Arrow, replicated, DpnI-resistant pJC433 DNA.
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FIG. 5. p53 does not repress JCV T-antigen expression. U87MG
cells were transfected with 3 mg of JC virus T-antigen expression
plasmid pRSV JCT and increasing amounts of pSG5 – mp53cD. pSG5
plasmid was added to bring the total amount of transfected DNA
to 8 mg. Protein samples were analyzed by Western blotting applying
the anti-p53 PAb421 and anti-T-antigen PAb416 antibodies. Lane 1,
without pSG5 – mp53cD; lanes 2, 3, and 4, 0.5, 1, and 5 mg of pSG5 –
mp53cD.
pears to be important but not solely responsible for re-
pressing JCV DNA replication. Moreover, deletion of the
C-terminal region hardly impairs the replication-repress-
ing activity. Structural motifs within the C-terminal region
determine the ability of p53 to form homologous com-
plexes (Stu¨rzbecher et al., 1992). Thus, it appears that
FIG. 4. Repression of JCV DNA replication by human p53. U87MG strong p53–p53 interaction is not required for the ob-
cells were transfected with 1 mg of each of the expression plasmids
served inhibitory activity of p53. This might be due topJC433, pRSVJCT and pSG5-hp53, respectively. Low-molecular-weight
a weak nontetrameric oligomerization domain recentlyDNA was extracted and analyzed by Southern blotting. Arrow, repli-
identified within amino acid 1–320 (Stenger et al., 1994).cated, DpnI-resistant pJC433 DNA.
Interaction between large T-antigen and p53, on the other
hand, is indispensable for the inhibitory activity of p53
on JCV DNA replication. Mutants that fail to bind to JCVmodel for the antiproliferative effect of wild-type p53, as
T-antigen are not able to repress JCV DNA replication init is consistent with the observation that mutant p53 has
vivo. In SV40 DNA replication, the initiation step report-lost its inhibitory effect on SV40 DNA replication both in
edly involves the binding of large T-antigen to DNA se-vitro and in vivo (Friedman et al., 1990; Miyamoto et al.,
quence elements comprising the origin of replication as1990). This is in analogy to the loss of a growth-inhibitory
two lobes, each containing a hexamer of large T-antigen,function of mutant p53 in cellular proliferation (Mercer et
followed by induction of structural distortions and grad-al., 1990; Michalowitz et al., 1990).
ual unwinding of the origin DNA (Borowiec et al., 1990).The SV40 large T-antigen binding domain of p53 over-
This unwinding of the SV40 origin of replication by largelaps the sequence-specific DNA binding domain within
T-antigen is the target of inhibition by p53 at least in vitrothe central region of the protein (Shaulian et al., 1992;
(Stu¨rzbecher et al., 1988; Wang et al., 1989). It is possibleRuppert and Stillman, 1993). This region of the p53 pro-
that any disturbance of this delicately balanced initiationtein contains mutational hotspots in human tumors. From
complex by the binding of JCV large T-antigen to p53our deletion analysis, the acidic transactivation domain
even without the formation of p53 self-aggregates wouldwhich is indispensable for stimulating transcription ap-
result in a disruption of the initiation process.
Growth suppression by p53 may be mediated
TABLE 3 through transcriptional control of specific target genes
Replicational Repression by Wild-Type p53 or by interaction with other cellular components or
and Tumor-Derived Mutants both. Binding of large T-antigen to wild-type p53 may
mimic the effect of tumor mutations and interfere with
% Replication
p53 function either by directly inhibiting DNA bindingp53 in U87MG cells
(Bargonetti et al., 1992) or by preventing interaction
Mock 100 { 6.8 with a cellular protein that facilitates DNA binding.
wt 22.5 { 7.3 Alternatively, large T-antigen binding could prevent
His 175 94.3 { 7.8 p53 association with other cellular proteins that medi-
His 273 25.4 { 10.3
ate the effect of p53 on growth control. Analogy with
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FIG. 6. (A) Interaction of murine p53 deletion mutants with the JCV large T-antigen. (a) In vitro translation of p53 deletion mutants. [35S]Methionine-
labeled p53 proteins were separated after translation by SDS–PAGE (15% polyacrylamide) and visualized by autoradiography. (b) Interaction of p53
with JC virus T-antigen in vitro. [35S]Methionine-labeled wtp53 and deletion mutants were incubated with JC virus T-antigen and coimmunoprecipitated
by anti-T-antigen antibody PAb416 coupled to protein A–Sepharose. Precipitates were separated by SDS–PAGE (15% polyacrylamide) and analyzed
by autoradiography. (B) Interaction of human p53 with the JCV large T-antigen. (a) In vitro translation of p53. [35S]Methionine-labeled p53 proteins
were separated after translation by SDS–PAGE (15% polyacrylamide) and visualized by autoradiography. (b) Interaction of p53 with JC virus T-
antigen in vitro. [35S]methionine-labeled murine (mu wt) and human (hu wt) wild-type and human mutant p53 (M175 and M273) was incubated with
JC virus T-antigen and coimmunoprecipitated by anti-T-antigen antibody PAb416 coupled to protein A–Sepharose. Precipitates were separated by
SDS –PAGE (15% polyacrylamide) and analyzed by autoradiography.
the retinoblastoma protein Rb suggests that, for each p53 results in a titration of free T-antigen and subse-
quent inhibition of viral DNA replication. Therefore, weof these tumor suppressor proteins, large T-antigen
assume that, in analogy to the functional eliminationcould recognize a protein binding domain that nor-
of free large T-antigen by excess p53 in in vitro replica-mally interacts with cellular factors to regulate growth.
tion assays, overexpression of wild-type p53 mightAdditionally, the inhibition of JCV DNA replication as
eliminate replicational activities of large T-antigen inwell as the SV40 DNA replication by p53 suggests a
vivo. More detailed analysis of p53 domains involvedcommon mechanism for at least the JCV and the SV40
in the regulation of viral and cellular DNA replicationpapovavirus to overcome the stringent cell cycle con-
should lead to new insights into fundamental mecha-trol by p53. The initiation of viral replication depends
nisms of cell cycle and growth control by p53.on the functional inactivation of endogenous p53,
since endogenously expressed wild-type p53 does not
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